# ABEO catalysts: ABEONA THERAPEUTICS INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/abeo/catalysts

> ABEONA THERAPEUTICS INC. (ABEO) has 1 upcoming catalyst. The next is the ABO-801 topline data readout, late 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | ABEONA THERAPEUTICS INC. |
| Ticker | ABEO (Nasdaq) |
| SEC CIK | 318306 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/abeo |

## Cash runway

Cash $134.9M as of 2026-09-30; quarterly burn $8.3M; about 48.7 months of runway at that rate (XBRL company facts, accession 0001493152-26-050738).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Nov 2022 | [VIITAL (viital) topline data readout](https://sec-api.dev/pdufa/viital) | ABEO |  | completed, positive | "In November 2022, we announced positive top-line data from the VIITAL™ study evaluating the efficacy, safety and tolerability of pz-cel." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/318306/000149315225010978/form10-k.htm)) |
| Nov 2023 | [ABEONA THERAPEUTICS INC. PDUFA date](https://sec-api.dev/companies/abeo/catalysts) | ABEO |  | scheduled | "In November 2023, the FDA accepted and granted priority review for our BLA for pz-cel, and subsequently, under the Prescription Drug User Fee Act ("PDUFA"), the FDA set a target action date of May" ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/318306/000149315225010978/form10-k.htm)) |
| April 16, 2024 | [ABEONA THERAPEUTICS INC. complete response letter (CRL)](https://sec-api.dev/companies/abeo/catalysts) | ABEO | with recessive dystrophic epidermolysis bullosa | completed, complete response letter | "April 16, 2024, we received a Complete Response Letter (a "CRL") related to our Biologics License Application ("BLA") for pz-cel for the treatment of patients with recessive dystrophic epidermolysis bullosa ("RDEB")." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/318306/000149315224045340/form10-q.htm)) |
| April 16, 2024 | [Prademagene complete response letter (CRL)](https://sec-api.dev/pdufa/prademagene) | ABEO |  | completed, complete response letter | "COMPLETE RESPONSE letter dated 04/16/2024 for BL 125807 to Abeona Therapeutics, Inc.." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA125807_20240416.pdf%22)) |
| May 25, 2024 | [ABEONA THERAPEUTICS INC. PDUFA date](https://sec-api.dev/companies/abeo/catalysts) | ABEO |  | scheduled | "In November 2023, the FDA accepted and granted priority review for our BLA for pz-cel, and subsequently, under the Prescription Drug User Fee Act ("PDUFA"), the FDA set a target action date of May 25, 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/318306/000149315225010978/form10-k.htm)) |
| May 25, 2024 | [ABEONA THERAPEUTICS INC. NDA/BLA acceptance](https://sec-api.dev/companies/abeo/catalysts) | ABEO |  | completed | "FDA accepted and granted priority review for our BLA for pz-cel, and subsequently, under the Prescription Drug User Fee Act ("PDUFA"), the FDA set a target action date of May 25, 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/318306/000149315225010978/form10-k.htm)) |
| Aug 2024 | [ABEONA THERAPEUTICS INC. complete response letter (CRL)](https://sec-api.dev/companies/abeo/catalysts) | ABEO |  | completed, complete response letter | "Abeona completed a Type A meeting in August 2024 where it aligned with the FDA on the content for the resubmission of the Company's BLA for pz-cel, its investigational first-in-class, autologous cell-based gene therapy currently in development for RDEB, including additional information to satisfy all Chemistry Manufacturing and Controls (CMC) requirements noted in the Complete Response Letter (CRL) issued in April 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000149315224045338/ex99-1.htm)) |
| Oct 2024 | [ABEONA THERAPEUTICS INC. NDA/BLA submission](https://sec-api.dev/companies/abeo/catalysts) | ABEO |  | completed | "October 2024, Abeona resubmitted its BLA for pz-cel to the FDA, seeking approval of pz-cel as a potential new treatment for patients with RDEB." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000149315224045338/ex99-1.htm)) |
| Nov 2024 | [ABEONA THERAPEUTICS INC. PDUFA date](https://sec-api.dev/companies/abeo/catalysts) | ABEO |  | scheduled | "Company in November 2024 that the BLA was accepted for review, with an assigned PDUFA target action date of April 29," ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/318306/000149315225010978/form10-k.htm)) |
| November 8, 2024 | [ABEONA THERAPEUTICS INC. NDA/BLA acceptance](https://sec-api.dev/companies/abeo/catalysts) | ABEO |  | completed | "The FDA notified the Company on November 8, 2024 that the BLA was accepted for review, with an assigned Prescription" ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/318306/000149315224045340/form10-q.htm)) |
| November 14, 2024 | [ABEONA THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/abeo/catalysts) | ABEO |  | completed | "Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000149315224045338/ex99-1.htm)) |
| March 20, 2025 | [ABEONA THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/abeo/catalysts) | ABEO |  | completed | "Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000149315225010981/ex99-1.htm)) |
| April 28, 2025 | [ABEONA THERAPEUTICS INC. FDA approval](https://sec-api.dev/companies/abeo/catalysts) | ABEO |  | completed, approved | "On April 28, 2025, the United States Food and Drug Administration ("FDA") approved our Biologics" ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/318306/000149315225021723/form10-q.htm)) |
| April 29, 2025 | [Prademagene PDUFA date](https://sec-api.dev/pdufa/prademagene) | ABEO |  | completed, approved | "The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of April 29, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000149315224044514/ex99-1.htm)) |
| April 29, 2025 | [ABEONA THERAPEUTICS INC. PDUFA date](https://sec-api.dev/companies/abeo/catalysts) | ABEO |  | scheduled | "FDA priority review of pz-cel Biologics License Application (BLA) progressing with Prescription Drug User Fee Act (PDUFA) target action date of April 29, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000149315225010981/ex99-1.htm)) |
| April 29, 2025 | [Prademagene FDA approval](https://sec-api.dev/pdufa/prademagene) | ABEO | wounds in adult and pediatric patients with RDEB | completed, approved | "April 29, 2025 - Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the U.S. Food and Drug Administration (FDA) has approved" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000164117225006548/ex99-1.htm)) |
| April 29, 2025 | [ABEONA THERAPEUTICS INC. NDA/BLA acceptance](https://sec-api.dev/companies/abeo/catalysts) | ABEO |  | scheduled | "FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of April 29, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000149315224045338/ex99-1.htm)) |
| May 9, 2025 | [ZEVASKYN (zevaskyn) FDA approval](https://sec-api.dev/pdufa/zevaskyn) | ABEO |  | completed, approved | "May 9, 2025, the Company entered into a definitive asset purchase agreement that transferred the rights to a PRV awarded to the Company following the FDA approval of ZEVASKYN®." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/318306/000149315226010413/form10-k.htm)) |
| May 15, 2025 | [ABEONA THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/abeo/catalysts) | ABEO |  | completed | "Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000164117225010514/ex99-1.htm)) |
| August 14, 2025 | [ABEONA THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/abeo/catalysts) | ABEO |  | completed | "Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000164117225023715/ex99-1.htm)) |
| September 2025 | [Eb-101 surgical application of rdeb wounds primary completion](https://sec-api.dev/pdufa/eb-101-surgical-application-of-rdeb-wounds) | ABEO | Epidermolysis Bullosa; Recessive Dystrophic Epidermolysis Bullosa; RDEB | delayed | "NCT05725018 (A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-09-30 (ESTIMATED); Lead Sponsor Abeona Therapeutics, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05725018)) |
| November 12, 2025 | [ABEONA THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/abeo/catalysts) | ABEO |  | completed | "Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000149315225021721/ex99-1.htm)) |
| March 17, 2026 | [ABEONA THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/abeo/catalysts) | ABEO |  | completed | "Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000149315226010408/ex99-1.htm)) |
| May 13, 2026 | [ABEONA THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/abeo/catalysts) | ABEO |  | completed | "Therapeutics® Reports First Quarter 2026 Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000149315226022610/ex99-1.htm)) |
| August 13, 2026 | [ABEONA THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/abeo/catalysts) | ABEO |  | completed | "Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000149315226037575/ex99-1.htm)) |
| November 9, 2026 | [ZEVASKYN (zevaskyn) earnings report](https://sec-api.dev/pdufa/zevaskyn) | ABEO |  | completed | "Therapeutics® Reports Third Quarter 2026 Financial Results and ZEVASKYN® Commercial Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000149315226050609/ex99-1.htm)) |
| late 2028 | [ABO-801 topline data readout](https://sec-api.dev/pdufa/abo-801) | ABEO |  | scheduled | "Phase 3 study in the second quarter of 2027 and, subject to the timing of study initiation and enrollment, currently anticipates topline results by the end of 2028." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000149315226050606/ex99-1.htm)) |

## Drugs

- [ABO-801](https://sec-api.dev/pdufa/abo-801): 
- [Eb-101 surgical application of rdeb wounds](https://sec-api.dev/pdufa/eb-101-surgical-application-of-rdeb-wounds): Epidermolysis Bullosa
- [Prademagene](https://sec-api.dev/pdufa/prademagene): wounds in adult and pediatric patients with rdeb
- [VIITAL (viital)](https://sec-api.dev/pdufa/viital): 
- [ZEVASKYN (zevaskyn)](https://sec-api.dev/pdufa/zevaskyn): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/abeo/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ABEO catalysts: ABEONA THERAPEUTICS INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/abeo/catalysts

```bibtex
@misc{secapidev_companies_abeo_catalysts_20261116,
  title        = {ABEO catalysts: ABEONA THERAPEUTICS INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/abeo/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_abeo_catalysts_20261116","title":"ABEO catalysts: ABEONA THERAPEUTICS INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/abeo/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
